NEW YORK, July 15, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Image Sensing
Systems, Inc. aTyr Pharma Inc. (NASDAQ: LIFE). Select highlights
from the internally released reports are being made available to
the general public (included below), with access to the entirety of
the research available to new members.
Today, membership is open to readers on a complementary basis at
the following URL: http://www.aciassociation.com/?c=LIFE
Highlights from our LIFE Report include:
- First Quarter 2015 Operating Results -- On June 18, 2015, aTyr Pharma Inc. a biotherapeutics
Company which was recently added to the Russell 2000®, Russell
3000® and Russell Global Indexes announced its Q1 2015 operating
results. During the reported quarter, its Research and development
expenses rose to $6.6 million from
$4.4 million in Q1 2014.
- Financial Performance During the Quarter -- During Q1
2015, its general and administrative expenses increased to
$2.3 million from $1.5 million in Q1 2014. Net loss attributable to
common stockholders for Q1 2015 stood at $9.1 million, or $9.39 loss per diluted share as compared to net
loss attributable to common stockholders of $6.2 million or $7.87 loss per diluted share in Q1 2014.
- Increase in Liquidity -- aTyr Pharma informed that its
cash, cash equivalents and investment securities as at March 31, 2015 stood at $54.5 million compared with $15.9 million as at March
31, 2014. Furthermore, on May 12,
2015, aTyr Pharma also completed its initial public offering
with estimated net proceeds of $76.9
million.
- Update on its Lead Candidate Resolaris™ -- The
Company noted that its lead candidate, Resolaris™, is undergoing a
Phase 1b/2 clinical trial in adult patients with
facioscapulohumeral muscular dystrophy (FSHD). aTyr Pharma expects
to report initial results from this clinical trial in Q4 2015 or
early 2016.
- Clinical Trials in Pipeline -- aTyr Pharma is also
planning to initiate a Phase 1b/2 clinical trial in early onset
FSHD patients which is expected to commence in Q3 2015. The Company
stated that post the evaluation of a number of muscular dystrophies
(MD), including Duchenne muscular dystrophy and a broad class of MD
indications of more than 20 rare genetic conditions known as the
limb-girdle muscular dystrophies (LGMD), the Company has selected
LGMD 2B as its next expansion indication after early onset FSHD.
Beginning in Q4 2015, the Company anticipates to move ahead with a
Phase 1b/2 clinical trial of Resolaris™ in LGMD 2B.
- Outlook -- The Company anticipates its research and
development expense to continue to increase with its Resolaris™
franchise expansion activities, including the clinical development
of Resolaris™. Moreover, aTyr Pharma also anticipates a substantial
increase in its general and administrative expenses in order to
support the continued development of its product candidates and the
costs associated with operating as a public company.
To find out how this influences our rating on aTyr Pharma Inc.,
read the full report in its entirety here:
http://www.aciassociation.com/?c=LIFE
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the CFA®
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com